Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals
2003 · Acquisition/Merger · $8.8B · Complete
Announcement Sentiment
75
Strongly positive
Outcome Score
82
Worked — the deal delivered on its rationale.
Takeda Pharmaceutical Co. acquired Millennium Pharmaceuticals for $25 per share (~$8.8 billion) in an all-cash tender offer, gaining Velcade (bortezomib) for multiple myeloma ($528M in 2007 revenue) and establishing a major US oncology presence. This was the largest overseas acquisition by a Japanese pharmaceutical company at the time.
Key facts
AnnouncedAug 17, 2003
ClosedMay 14, 2008
Deal value$8.8B
Deal typeAcquisition/Merger
Therapeutic areaGastroenterology, Oncology
IndicationsMultiple Myeloma, Mantle Cell Lymphoma
Key assetsVelcade (bortezomib), Oncology pipeline, Cambridge MA research center